About this trial
Withdrawal management strategies are currently the most utilized and ubiquitous intervention for opioid use disorder in the US, yet existing measures of opioid withdrawal lack Food and Drug Administration (FDA) qualification. This project will develop and validate a clinical outcome assessment (COA) for opioid withdrawal,essential for standardizing withdrawal mitigation strategies and establishing best practices. In line with the FDA's drug development tool qualification guidelines, our methodological process will involve conducting focus groups with persons with lived experience of opioid withdrawal for concept elicitation, refining these concepts through cognitive interviews, and conducting construct and longitudinal validations of the new assessment in laboratory settings and across diverse treatment contexts.
Eligibility criteria
Qualifiers
Past year opioid use disorder, determined by (a) enrollment in current treatment for opioid use disorder and/or (b) an opioid-positive saliva test.
Fluent in English
Has experience with opioid withdrawal at least once in the past 30 days
Disqualifiers
Unable to provide informed consent due to cognitive impairment
Being pregnant or breastfeeding
History of psychosis or mania as determined by the MINI
Exhibiting suicidal behavior in the past 30 days as determined by the C-SSRS
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
University of Maryland, Baltimore
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator